Limor Helpman

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

Brca1/2 Mutation, Medicine, Cancer Management +10

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 391 citations · Full text

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Domenica Lorusso, Yang Xiang, Kosei Hasegawa et al. · The Lancet · 2024 · 130 citations

Advanced Cervical Cancer, Cervical Cancer Management, Cervical Cancer +10

Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer

Limor Helpman, Rachel Kupets, Al Covens et al. · British Journal of Cancer · 2013 · 118 citations · Full text

Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death

Amy Jamieson, Jutta Huvila, Derek S. Chiu et al. · Modern Pathology · 2023 · 90 citations · Full text

Medicine, Low Risk, Gynecology +6